Your session is about to expire
← Back to Search
Cabozantinib for Endometrial Cancer
Study Summary
This trial studies cabozantinib s-malate for endometrial cancer. Cabozantinib s-malate may stop tumor growth by blocking enzymes and blood flow to the tumor.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had allergic reactions to similar drugs as XL184.My blood, liver, and kidney functions meet the required levels.My cancer has grown or spread after my last treatment.I do not have uncontrolled heart, stomach issues, or other major health problems.I can swallow tablets, my heart rhythm is normal, and I agree to follow the study rules.I am not pregnant, breastfeeding, or HIV-positive on antiretroviral therapy.My endometrial cancer has spread and is confirmed by lab tests.I can take care of myself but might not be able to do heavy physical work.I have recently used chemotherapy, biologic agents, or radiotherapy.I have been treated with cabozantinib before.You are expected to live for at least 3 more months.I have had one round of chemotherapy or hormone therapy for my cancer that has spread or come back.
- Group 1: Treatment (cabozantinib s-malate)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there more than one location in this city where this research is taking place?
"To limit the burden of travel on participants, it is advisable to select a clinical trial site nearest to your location. Out of the 20 active sites, there are locations in South Pasadena, Indianapolis and Edmonton among others."
What are the primary purposes of Cabozantinib S-malate?
"While cabozantinib S-malate is most commonly used as a second line of defense against anti-vegf, it has also been shown to be effective in the treatment of advanced renal cell carcinoma (arcc), adrenal medulla, and high risk patients."
What is unique about this clinical trial?
"Since 2012, there has been an uptick in research concerning Cabozantinib S-malate. 86 patients were studied initially in 2012 under the auspices of Exelixis. The data from that first Phase 2 trial was promising and resulted in drug approval. As it stands, there are 116 ongoing trials for this medication across 1375 cities and 46 countries."
How many people are participating in this research project?
"Unfortunately, this particular trial is not presently recruiting patients. Although, it's important to note that the study was updated as recently as October 15th of this year. There are presently 4254 clinical trials searching for participants with malignant neoplasms and 116 studies involving Cabozantinib S-malate are also admitting patients."
Are people currently enrolling in this clinical trial?
"Unfortunately, this particular clinical trial is no longer looking for patients. The study was first posted on April 29th 2013 and received its last update October 15th 2022. However, there are 4254 other trials currently recruiting participants with malignant neoplasms and 116 studies for Cabozantinib S-malate that are still admitting patients."
What is the regulatory status of Cabozantinib S-malate?
"Because this is a Phase 2 trial, there is only data supporting Cabozantinib S-malate's safety but not efficacy. We scored it a 2."
What is the existing research on Cabozantinib S-malate?
"116 studies are currently underway to research Cabozantinib S-malate with 13 of those in the third stage of clinical trials. The majority of these trials taking place Cordoba and Calabria, but there are 7151 total locations spread out across researching this medication."
Share this study with friends
Copy Link
Messenger